



IMDX TO RELEASE THIRD QUARTER 2025 RESULTS ON NOVEMBER 10 AND ATTEND STEPHENS ANNUAL INVESTMENT CONFERENCE THE FOLLOWING WEEK

Nov 03, 2025

NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 10, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.

The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: [iMDX Q3 2025 Earnings Webinar](#).

An archived replay will be available after the call concludes on iMDX's investor relations website at <https://investors.imdxinc.com/>.

Stephens NASH25 Conference

Separately, on November 19th, Chief Executive Officer Josh Riggs will attend the Stephens NASH25 Conference, taking place from November 18-20, 2025.

Investors wishing to book one-on-one meetings with management are encouraged to reach out to their Stephens sales representative.

Event: Stephens NASH25 Conference

Dates: November 19, 2025

Location: Nashville, TN

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering precision diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. iMDx utilizes a well-established proprietary approach to quantify dd-cfDNA, which is a widely used molecular biomarker of transplant rejection.

iMDx™, GraftAssure™, GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company's new NASDAQ symbol became effective June 18. Investors may visit <https://investors.imdxinc.com/> for more information.

Investor Contact:

Doug Farrell

LifeSci Advisors LLC

dfarrell@lifesciadvisors.com



Source: Insight Molecular Diagnostics Inc.

